bluebird bio (BLUE) – Company Press Releases
-
BLUEBIRD BIO, INC. (NASDAQ: BLUE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
BLUE Lawsuit: Robbins LLP Reminds Investors of bluebird bio, Inc. of Pending Lead Plaintiff Deadline
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
BLUEBIRD BIO, INC. (NASDAQ: BLUE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against bluebird bio, In
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
bluebird bio, Inc. (BLUE) Class Action Notice: Robbins LLP Reminds Stockholders of Lead Plaintiff Deadline in Class Action Against bluebird bio, Inc.
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Blue, and Luna Innovations and Encourages Investors to Contact the Firm
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
BLUEBIRD BIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (NASDAQ: BLUE)
-
BLUE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm
-
BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead the bluebird bio Class Action Lawsuit
-
BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm
-
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
-
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
-
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
-
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
-
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
-
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
-
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
-
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independ
-
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Re
-
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
-
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
-
Engine Capital Sends Letter to 2seventy’s Board of Directors Outlining Steps to Maximize Shareholder Value
-
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
-
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
-
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
-
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
-
bluebird bio Announces September Investor Events
-
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
-
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
-
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
-
Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer
-
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History
-
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
-
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
-
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusiv
-
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
-
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
Back to BLUE Stock Lookup
